Viking Therapeutics' stock surged 9.91% in post-market trading on Wednesday, as investors focused on encouraging updates across the company's clinical development pipeline, overshadowing a wider-than-expected fourth-quarter loss.

The biopharmaceutical company reported a Q4 net loss of $157.7 million, or $1.38 per share, which missed analyst estimates. However, the market reaction was driven by several key announcements regarding its obesity drug portfolio. Viking Therapeutics plans to advance its oral VK2735 formulation into Phase 3 trials for obesity in the third quarter of 2026. The company highlighted that the availability of both an oral and an injectable formulation is a key differentiator for VK2735, as no other dual or triple agonist is currently available in both forms.

Additional positive updates included strong enrollment progress in the Phase 3 VANQUISH trials for the subcutaneous formulation of VK2735, the completion of enrollment for a VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an Investigational New Drug (IND) application for a novel amylin agonist this quarter. The company also reported a strong cash position of $706 million at year-end, providing ample resources to advance its clinical programs.